Combined C-reactive protein, procalcitonin, and microalbuminuria panel for contrast-induced nephropathy risk stratification after percutaneous coronary intervention
Cancer patients with cardiovascular comorbidities requiring contrast-based cardiac procedures face substantially amplified risk for contrast-induced nephropathy (CIN), driven by anticancer therapy-related systemic inflammation, nephrotoxicity, and endothelial dysfunction. Validated biomarker-based risk stratificati...